Objective. Describe obstetrical providers' management of a hypothetical case on chronic pain in pregnancy and determine whether practices differ based on patient race.
Methods. A case-vignette described a pregnant patient presenting with worsening chronic lower back pain, requesting an opioid refill and increased dosage. We varied patient race (black/white) across two randomly assigned identical vignettes. Providers indicated their likelihood of prescribing opioids, drug testing, and referring on a 0 (definitely would not) to 10 (definitely would) scale; rated their suspicions/ concerns about the patient on a 0-10 VAS scale; and ranked those concerns in order of importance. We calculated correlation coefficients, stratifying analyses by patient race.
Results. Providers were not inclined to refill the opioid prescription (median 5 3.0) or increase the dose (median 5 1.0). They were more likely to conduct urine drug tests on white than black patients (P 5 0.008) and more likely to suspect that white patients would divert the medication (P 50.021). For white patients, providers' highest-ranked concern was the patient's risk of abuse/addiction, whereas, for black patients, it was harm to the fetus. Suspicion about symptom exaggeration was more closely related to decisions about refilling the opioid prescriptions and increasing the dose for black patients (r 5 20.357, 20.439, respectively), whereas these decisions were more closely correlated with concerns about overdose for white patients (r 5 20.406, 20.494, respectively).
Conclusions. Provider suspicion and concerns may differ by patient race, which may relate to differences in pain treatment and testing. Further study is warranted to better understand how chronic pain is managed in pregnancy.
Introduction
In recent years, prescription pain medication abuse and misuse has grown to epidemic proportions [1] . In 2012, it was estimated that 2.1 million people in the United States suffered from prescription opioid drug abuse [2] . This statistic arises amidst a background of opioid prescriptions increasing nationally from 76 million in 1991 to 207 million in 2013 [2] . These numbers can be attributed, in part, to widespread efforts to ensure adequate treatment of pain in healthcare settings [3] , but also to the rise in chronic pain symptoms-now estimated to impact more than 100 million Americans [4] -particularly among women of reproductive age [3, 5] . In light of the disproportionate rise in chronic pain and opioid use among young women, obstetricians, more than ever before, face the challenge of managing pregnant patients with chronic pain and chronic opioid use and, potentially, physical dependence [6, 7] . Opioid agonist therapies have long been the accepted form of treatment for opioid use disorder in pregnancy [6, 8] . However, there are limited data to guide the care of pregnant women who chronically use or abuse prescription analgesics, aside from that which can be extrapolated from the literature on heroin addiction and pregnancy [9, 10] . In addition to having limited guidance for chronic pain management, providers are also faced with growing concerns about the prevalence of opioid use in pregnancy and the rising rates of neonatal abstinence syndrome (NAS) in newborns [11] . Though it remains unclear from the existing research whether symptoms of NAS are more strongly related to socio-environmental factors or opioid-related factors [12] , heightened media and policy attention to NAS has resulted in increased scrutiny surrounding obstetricians' prescribing practices for pain medication and opioid agonists in pregnancy [13] [14] [15] .
Several studies have analyzed physicians' practice patterns across a range of pain conditions [16, 17] . However, little research exists on the current practices of opioid management during pregnancy [18] [19] [20] [21] . Additionally, though there is evidence that racial disparities exist in the provision of pain treatment [22] and opioid monitoring [23] , as well as in patterns of drug testing, reporting, and monitoring among pregnant black women [23] [24] [25] , few studies have examined the impact that patient race has on obstetrical prescribing patterns. In an attempt to expand our understanding of how general obstetrical providers approach managing chronic pain in pregnant patients, we conducted a vignettebased pilot study using experimental methodology with obstetrician-gynecologists to identify opioid prescribing and urine drug testing practices for the management of chronic pain in pregnancy. As a secondary aim, we examined differences in prescribing and drug testing patterns based on patient race.
Methods

Study Population
With approval from the Indiana University Institutional Review Board, we recruited a convenience sample of obstetrical providers attending the American College of Obstetrics and Gynecology District V and VII Annual Meeting from October 10-11, 2014. General obstetrician-gynecologists (OB/GYN), maternal-fetal medicine (MFM) specialists, OB/GYN residents, and nurse practitioners (NPs) practicing in the United States were included. Physicians in "Gyn-only" practice settings or Gyn subspecialties (reproductive endocrinology and infertility, uro-gynecology, or gyn-oncology) were ineligible to participate.
Study Design
Participants were asked to complete a five-page study packet, which included a clinical case vignette and a demographics questionnaire. Participants were recruited from a booth on the exhibit hall and received $20 for their participation. The vignette was adapted from previously published studies of management of chronic back pain [26] [27] [28] . Our team of investigators, with input from outside experts in pain medicine and obstetrics, developed the vignettes and piloted the instrument among practicing OB/GYNs to ensure that relevant information needed for a decision about pain management was presented. The vignette described a pregnant patient with a history of chronic lower back pain who complains of worsening pain since becoming pregnant. The patient is due for a refill on her opioid prescription, and requests an increase in her dose. We varied patient race (black/white) in the vignette, across two otherwise identical versions of the survey. Alternating "black" and "white" versions of the survey were distributed on a 1:1 basis to ensure equal allocation and random assignment. The demographics questionnaire queried practice characteristics (state, [sub]specialty, practice model, practice setting, resident supervision) and personal characteristics (age, gender, years in practice, race/ethnicity, and religious and political affiliation).
Outcomes
After reading the vignette, participants were asked to rate their likelihood of performing each prescribing practice on a scale from 0 (definitely would not) to 10 (definitely would). Based on previously published items [26] [27] [28] , prescribing practices included: refill the opioid prescription; increase the dose of the opioid medication; obtain a urine drug test; counsel the patient on NAS; accept the patient into their practice; refer the patient to a MFM specialist; and refer the patient to a pain specialist or clinic. Providers were also asked to indicate the medication they would likely prescribe for the patient and to indicate the number of tablets and refills they would prescribe. Participants were then asked to use a 100 mm visual analog scale (VAS) (anchored at 0-none and 100-extremely) to quantify the degree to which they were concerned about the following: the patient exaggerating her pain; the patient having an ulterior motive; the patient diverting the medication; the patient abusing or becoming addicted to the medication; the fetus being harmed; the patient overdosing; and statutes or regulations on opioid prescribing. Lastly, participants were asked to rank the aforementioned concerns from greatest to least importance.
Analysis
Univariate statistics were used to describe the study population and provide summary statistics on participants' likelihood ratings, VAS responses, and rankings. Because the responses were not normally distributed, Kruskal-Wallis tests were used for bivariate analyses. Correlation coefficients were also calculated to assess the strength of associations between the physicians' prescribing patterns and their suspicions or concerns regarding the patients' motives and potential adverse events. Data were analyzed with SPSS 21 (IBM, Chicago, IL, USA).
Results
Seventy-seven providers completed the survey among a total of 180 eligible attendees (43% response rate). Table 1 describes the demographic characteristics of the respondents. Respondents were predominantly white (68.8%), female (67.5%) OB/GYN generalists (91.2%) practicing in urban environments (66.3%). A variety of practice settings were represented, including partnership groups (29.9%), university settings (20.8%), individual practice (13%), and multi-specialty groups (3.9%). With the exception of practice location, resident supervision, and political affiliation, most physician demographic characteristics were not associated with the practice of refilling opioid prescriptions or performing urine drug tests. Table 2 characterizes the opioid prescribing practices and suspicions/concerns of the respondents, overall and separated by patient race. Overall, most providers were inclined to report that they would counsel the patient about NAS (median ¼ 10 on a 0-10 scale), refer the patient to a pain specialist (median ¼ 9), accept the patient into their practice (median ¼ 7), and switch to a non-opioid pain medication (median ¼ 6). When asked to indicate the medication they would likely prescribe for the patient, 22 out of the 77 respondents (29%) reported that they would prescribe an opioid, with an average number of 30 pills given. Providers were less inclined to report feeling compassion for their patient (median ¼ 4), to refill the opioid prescription (median ¼ 3), or increase the current dose (median ¼ 1). Although providers were likely to order a urine drug screen (UDS) in both populations (median ¼ 9), they were significantly more likely to order a UDS for white patients than black patients (P ¼ 0.008). Otherwise, there were no significant differences in provider prescribing patterns with respect to patient race.
With regard to suspicions and/or concerns, overall, providers reported being especially concerned about the potential for abuse and addiction (median ¼ 7.6 on 0-10 scale), harm to the fetus (median ¼ 7.3), and opioid prescription statues or regulations (median ¼ 6.8).
Over half of providers suspected that the patient was exaggerating (median ¼ 5.7) or had ulterior motives (median ¼ 5.6). Providers reported being relatively less concerned about patient overdose (median ¼ 5.0) and diversion (median ¼ 4.4); however, they were significantly more likely to suspect white patients of diversion than black patients (P ¼ 0.021). Table 3 presents the correlation coefficients for physician suspicions/concerns and their prescribing and referral behaviors. Overall, prescribing and drug testing practices, along with referral patterns, were significantly correlated with suspicions about exaggeration and ulterior motives and with concerns about overdose and fetal harm. Notably, these correlations differed by race. Regarding treatment and testing behaviors, for black patients, suspicions about exaggeration and ulterior motives were negatively correlated with refilling the opioid prescription (À0.357, exaggeration) and increasing the dose (À0.439, exaggeration; À0.393, ulterior motives), while these suspicions were positively correlated with obtaining urine drug testing (0.364, exaggeration). For white patients, treatment and testing behaviors were related to concerns about overdose and fetal harm. Specifically, concern about overdose was negatively correlated with refilling the opioid (À0.406), increasing the dose (À0.494), and switching to a non-opioid pain reliever (À0.318), while concern about fetal harm was positively correlated with obtaining a urine drug test (0.321) and counseling on NAS (0.390). With regard to referral patterns, suspicions about exaggeration and ulterior motives were negatively correlated with providers accepting white patients into their practices (À0.586 and À0.556, respectively), while suspicion of an ulterior motive was negatively correlated with referring black patients to a pain clinic (À0.468). Lastly, concerns regarding statutes regulating prescribing were positively correlated with switching black patients to non-opioid medications (0.366) and negatively correlated with increasing the dose for white patients (À0.319).
Finally, when asked to rank the six "suspicion/concern" items in order from most to least important, the three concerns most frequently ranked #1 were opioid abuse (42%), harm to the fetus (32%), and diversion (6%). Fetal harm was the most frequent response for the #2 ranked concern, and 25% of the respondents ranked it as their top concern. Though 70% of providers rated statutes and regulations as a factor influencing their willingness to prescribe, regulations ranked lowest among provider concerns relative to the other patient-related factors. Table 4 presents the modal response rankings by patient race. When stratified by patient race, fetal harm was most frequently ranked as the top concern (followed by potential for opioid abuse) for black patients, while potential for opioid abuse (followed by fetal harm) was the primary concern for white patients. 
Discussion
We conducted a vignette-based, pilot survey to describe opioid prescribing and urine drug testing practices for the management of chronic pain in pregnancy. Our secondary aim was to determine whether these practices differed based on patient race. In a sample of obstetrical providers attending an ACOG district meeting, we found that providers were most likely to report that they would counsel pregnant patients about NAS, refer patients to a pain specialist, and switch the current prescription from an opioid to a non-opioid pain medication. Providers were less likely to report that they would refill the opioid prescription or increase the current dose. With regard to urine drug testing, providers were more likely to report that they would test the white patient than the black patient, and more likely to suspect that the white patient would divert the medication. For the white patient, providers were primarily concerned about the risk of abuse or addiction, whereas, for the black patient, the primary concern was harm to the fetus. Furthermore, with the exception of accepting patients into their practice, suspicion about symptom exaggeration was more closely related to treatment ratings for black patients; whereas concerns about overdose and harm to the fetus were more closely related to treatment ratings for white patients.
Few, if any, previous empirical studies have explored obstetricians' management of chronic pain in pregnancy. We were surprised to find that the majority of providers were likely to switch the patient to a nonopioid medication, given that clinical guidelines currently caution against triggering opioid withdrawal during pregnancy, because withdrawal has been associated with adverse fetal outcomes [29] . Given the patient's long-term use of opioid medication (as specified in the vignette), she would be at high risk of physical dependence and potential withdrawal. Indeed, given a relative lack of expertise in opioid management among obstetrical providers, there is a greater likelihood of poor weaning, potentially increasing the chance of adverse events for the patient and/or the fetus. Further, providers were reluctant to increase the dose of the patient's pain medication, though it is established that opioid requirements in patients on chronic opioid therapy tend to increase during the course of pregnancy [29] . It was also noteworthy that providers were very likely to indicate that they would refer the patient to an addiction specialist. While this may be an appropriate course of action for some patients, access to addiction specialists for pregnant and parenting women remains severely limited by supply versus demand and financial/payer constraints. Finally, in light of a nationwide movement to put legislation in place to restrict, monitor, and, potentially, penalize physicians' prescribing practices, it is not surprising that almost 70% of respondents indicated that statutes and regulations impacted their willingness to prescribe opioids to the patient [30, 31] . Indeed, actions by the Drug Enforcement Agency (DEA) that changed hydrocodone from Schedule III to Schedule II and tramadol (previously not a controlled substance) to a Schedule IV drug [32] , along with legislation in an increasing number of states aimed at governing opioid prescribing [33] , have significantly changed the opioid prescribing landscape in recent years. In light of these changes, it is not surprising that prescribing practices were significantly correlated with concerns about such regulations. It remains to be seen how such regulations will ultimately impact pain care-whether they improve pain management practices and patient outcomes or whether they serve as an additional barrier to receiving appropriate and needed care.
Providing good clinical care for chronic pain patients can be challenging given the subjective nature of pain, physical and psychosocial comorbidities, and the abuse potential of many analgesic medications. Such a complicated context is ripe for bias, conscious and unconscious, to intrude on clinical decision-making. Previous studies suggested that black patients were more likely to be undertreated for pain, screened or tested for drugs, and reported to the criminal justice system and/ or social services [23, 25, 28, 34] . Therefore, we were surprised to find that white patients were more likely to be drug tested by our study participants. Interestingly, white patients were also more likely to evoke concerns for diversion among our study participants. If providers assumed that black patients were, in fact, using the opioids, but suspected that the white patients were more likely to be selling them, this might explain the disparate drug testing finding. A negative urine drug test would confirm suspicions regarding diversion, whereas a positive drug test in a patient admitting to use yields the provider no additional clinically useful information.
Alternatively, it is possible that we are observing the effect of a "shifting standard," wherein stereotyped expectations invite the use of different evaluative standards for members of different social groups. Members of stereotyped groups tend to be judged relative to group-specific standards such that subjective descriptions mean something different when they are applied to members of different groups [35] [36] [37] . In developing the vignette-which depicted a young, single mother with limited education and a history of a sexually transmitted disease-we may have evoked a shifting standard wherein the patient, when Refill opioid prescription 3.00 (1.00-6.00) 3.00 (1.00-7.00) 3.00 (0.50-5.00) 0.549 Increase dose of opioid medication 1.00 (0.00-3.00) 1.00 (0.00-3.00) 2.00 (0.00-3.00) 0.924 Switch patient to non-opioid medication 6.00 (3.00-8.00) 6.00 (2.00-9.00) 6.00 (3.50-8.00) 0.793
Obtain a urine drug test 9.00 (5.00-10.00) 7.00 (3.25-10.00) 10.00 (7.00-10.00) 0.008 Counsel patient on NAS prior to prescribing 10.00 (7.25-10.00) 10.00 (7.00-10.00) 10.00 (7.50-10.00) 0.894
Accept patient into practice 7.00 (5.00-10.00) 7.00 (5.00-10.00) 8.00 (5.00-10.00) 0.519 Refer patient to MFM 5.00 (3.00-9.00) 5.00 (2.00-9.00) 5.00 (3.00-9.75) 0.287 Refer patient to pain specialist/clinic 9.00 (8.00-10.00) 9.00 (8.00-10.00) 9.00 (8.00-10.00) 0.824
Experience compassion for the patient 4.00 (4.00-5.00) 5.00 (4.00-6.00) 4.00 (3.75-5.00) 0.103
Number of refills provided (if narcotic) Table 3 Correlations between provider prescribing practices and suspicions/concerns, N described as a black woman, simply confirmed stereotypes associated with black women, but strikingly defied expectations of a "typical" white woman. In doing so, we may have inadvertently heightened participants' suspicions and concerns about the white patient. It is also noteworthy that the primary concern about prescribing opioids to the black patient was harm to the fetus, while the primary concern for the white patient was the potential for abuse or addiction. This may relate to the salience of stereotypes related to black "welfare queens" and "crack babies," and notions of societal burdens that follow. Along similar lines, it is interesting that providers' prescribing and referral practices were more closely related to suspicions about black patients' motives, as compared to their concerns about overdose and fetal harm in white patients. This, too, may harken to stereotyped notions regarding black patients' behavior and character.
As a pilot, survey-based study, several limitations should be considered in interpreting our findings. First, given the relatively small sample size, these findings may not be generalizable. Likewise, as a convenience sample of providers attending an ACOG district meeting, our sample may not be representative of other obstetrical providers across the nation. While we did have fair representation of providers caring for patients in a variety of practice settings, by virtue of recruiting at a district meeting, regional representation was limited. That said, combined, the districts represented 13 states in the Midwestern and Southern regions of the country [38] . It is possible, however, that prescribing practices might differ substantially in less culturally and/or politically conservative regions of the country. We also recognize that, by virtue of being active in their professional organization, meeting attendees may be more knowledgeable about current clinical guidelines and evidence-based practices. However, we would expect selection bias of this sort to overestimate adherence to clinical guidelines in our population. Given the unexpected direction of the association between race and drug testing practices, it is possible that social desirability may have influenced some of the providers' responses, despite the anonymous nature of the surveys. While we did obtain input from practicing providers, it is important to acknowledge that the case vignette was not validated using a formal methodology for content validation, which may raise concerns regarding its representativeness of an actual patient scenario. Nonetheless, future research should ensure generalizability to other scenarios. Lastly, we fully recognize that this was not a study of actual practice patterns and acknowledge that providers' selfreport of potential behavior may not fully reflect their actual practices. And though vignette-based case studies are readily utilized in provider educational assessments and practice pattern research, empirical evidence is lacking on the relationship between providers' responses to clinical vignettes and their actual clinical practice.
Despite these limitations, this study provides an important foundation for understanding obstetrical opioid prescribing practices in an important and understudied setting and provides useful insights into obstetrical decision-making and practice patterns. While the rise of opioid abuse and neonatal abstinence syndrome are rightly a cause for concern, the heightened attention, from professional organizations, the media, and legislators alike, may lead to a growing reluctance to treat chronic pain in pregnancy adequately, as obstetricians become suspicious of their patients' motives and fearful of the legal implications of prescribing opioids to pregnant patients. This may result in pregnant patients receiving inadequate and potentially harmful treatment in the antenatal setting. To that end, greater education and guidance related to opioid withdrawal and appropriate opioid management in pregnancy may be needed for obstetrical providers. Furthermore, provider attitudes about treating chronic pain patients may affect their behaviors. Our findings may be explained, in part, by factors such as provider knowledge, attitudes, and perceptions about chronic pain management, which points to the need for future research evaluating the relationship between provider knowledge and perceptions and practice patterns. Moreover, further research is needed to understand the impact of changing attitudes about opioid prescribing, state and hospital policies on clinical decision-making, and how these changes may affect the doctor-patient relationship. Moreover, these clinical decisions are further fraught with the risk of unconscious bias resulting in differential treatment. Our findings raise important questions that warrant further study if we are to ensure 
